Patient and donor characteristics and GVHD incidence
. | No. . | Range . |
|---|---|---|
| Recipient-donor pairs studied, n | 60 | — |
| Recipient median age, y | 46.5 | 10-70 |
| Donor median age, y | 44.5 | 16-76 |
| Recipient sex, n, M/F | 43/17 | — |
| Donor sex, n, M/F | 35/25 | — |
| Male recipient of female donor, n (%) | 18 (30) | — |
| Recipient diagnosis, n | ||
| Non-Hodgkin lymphoma | 20 | — |
| Acute myeloid leukemia | 16 | — |
| Chronic myeloid leukemia | 11 | — |
| Acute lymphoid leukemia | 3 | — |
| Chronic lymphoid leukemia | 4 | — |
| Multiple myeloma | 2 | — |
| Hodgkin disease | 2 | — |
| Other | 2 | — |
| Conditioning regimen, n | ||
| Busulphan/cyclophosphamide | 17 | — |
| TB1/cyclophosphamide | 3 | — |
| BEAM | 14 | — |
| Fludarabine/melphalan | 6 | — |
| Fludarabine/busulphan | 1 | — |
| Fludarabine/idarubicin/cytarabine | 6 | — |
| Fludarabine/cyclophosphamide | 8 | — |
| Fludarabine/cisplatin/cytarabine | 5 | — |
| GVHD prophylaxis, n | ||
| Tacrolimus/low-dose methotrexate | 58 | — |
| Tacrolimus | 1 | — |
| Cyclosporine/prednisone | 1 | — |
| Median infused values | ||
| TNC, × 108/kg | 5.97 | 1.05-18.32 |
| CD34+, 106/kg | 4.47 | 2.56-7.1 |
| CD3+, 106/kg | 178.1 | 41.3-558.6 |
| CD4+, 106/kg | 109.3 | 23.1-268.2 |
| CD8+, 106/kg | 63.2 | 11.6-130.1 |
| Follow-up, d | 330 | 67-1310 |
| GVHD, n | ||
| Acute | 9 (15)* | — |
| Chronic | 11 (18)† | — |
| Acute + chronic | 13 (22)‡ | — |
| No GVHD, n | 27 (45) | — |
. | No. . | Range . |
|---|---|---|
| Recipient-donor pairs studied, n | 60 | — |
| Recipient median age, y | 46.5 | 10-70 |
| Donor median age, y | 44.5 | 16-76 |
| Recipient sex, n, M/F | 43/17 | — |
| Donor sex, n, M/F | 35/25 | — |
| Male recipient of female donor, n (%) | 18 (30) | — |
| Recipient diagnosis, n | ||
| Non-Hodgkin lymphoma | 20 | — |
| Acute myeloid leukemia | 16 | — |
| Chronic myeloid leukemia | 11 | — |
| Acute lymphoid leukemia | 3 | — |
| Chronic lymphoid leukemia | 4 | — |
| Multiple myeloma | 2 | — |
| Hodgkin disease | 2 | — |
| Other | 2 | — |
| Conditioning regimen, n | ||
| Busulphan/cyclophosphamide | 17 | — |
| TB1/cyclophosphamide | 3 | — |
| BEAM | 14 | — |
| Fludarabine/melphalan | 6 | — |
| Fludarabine/busulphan | 1 | — |
| Fludarabine/idarubicin/cytarabine | 6 | — |
| Fludarabine/cyclophosphamide | 8 | — |
| Fludarabine/cisplatin/cytarabine | 5 | — |
| GVHD prophylaxis, n | ||
| Tacrolimus/low-dose methotrexate | 58 | — |
| Tacrolimus | 1 | — |
| Cyclosporine/prednisone | 1 | — |
| Median infused values | ||
| TNC, × 108/kg | 5.97 | 1.05-18.32 |
| CD34+, 106/kg | 4.47 | 2.56-7.1 |
| CD3+, 106/kg | 178.1 | 41.3-558.6 |
| CD4+, 106/kg | 109.3 | 23.1-268.2 |
| CD8+, 106/kg | 63.2 | 11.6-130.1 |
| Follow-up, d | 330 | 67-1310 |
| GVHD, n | ||
| Acute | 9 (15)* | — |
| Chronic | 11 (18)† | — |
| Acute + chronic | 13 (22)‡ | — |
| No GVHD, n | 27 (45) | — |
Numbers in parentheses are percentages.—indicates no range possible.
One patient had stage 1 disease, and 8 had stages II-IV disease.
Two patients had limited disease, and 9 had extensive disease.
Three patients had stage I disease, and 10 had stages II-IV disease. Four patients had limited disease, and 9 had extensive disease.